• February 25, 2019
• 0

Roche and Spark Therapeutics have announced they are to enter a definitive merger agreement for Roche to fully acquire Spark for $4.3bn - the first company to gain approval for...

• February 18, 2019
• 0

Roche has bagged NICE backing for Perjeta (pertuxumab) in the prevention of early-stage HER2-positive breast cancer from recurring after surgery, after three attempts. The new draft guidance permits Perjeta to be given...

• February 5, 2019
• 0

Roche is aiming to hasten use of its breast cancer drug Kadcyla with the submission to the FDA under the Real-Time Oncology Review and Assessment Aid programme. Kadcyla (trastuzumab emtansine)...